Gore Global Registry for Endovascular Aortic Treatment Reaches 2,500 Enrolled Patients
Milestone Achievement in Monitoring Patient Outcomes and Device Performance
First Patient Enrolled in GORE® TAG® Thoracic Branch Endoprosthesis Early Feasibility Study
First Early Feasibility Study of a Gore Device Will Assess Treatment of Aortic Arch Aneurysms
Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure
Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet therapy alone
Gore Joins Vascular and Endovascular Leaders in Recognizing the 2016 Pioneers in Performance for North America
Leading Practitioners and Researchers from North America Commended for Commitment to Advancing Vascular and Endovascular Therapy
FDA Approves GORE® VIABAHN® Endoprosthesis for Revision of the Arteriovenous Access
Flexibility and Durability to Aid Hemodialysis Patients
Gore REDUCE Clinical Study Completes Enrollment
Study of Closure of Patent Foramen Ovale (PFO) in Stroke Patients Reaches Major Milestone
Gore Recognized as one of the Worlds Best Multinational Workplaces by Great Place to Work®
Company earns No. 3 spot
Gore Joins Americas Hernia Society Quality Collaborative (AHSQC) as Silver Sponsor
Partnership latest step in Gore’s ongoing commitment to improve quality of care for hernia patients
Gore Global Registry for Endovascular Aortic Treatment Completes Enrollment
Over 5,000 patients from 114 worldwide sites provide a unique perspective of real-world conditions
GORE® TIGRIS® Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease
Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies